English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe incidence of non-alcoholic fatty liver disease (NAFLD) and alcohol-associated liver disease (ALD) is increasing year by year due to changes in the contemporary environment and dietary structure, and is an important public health problem
Tag: Fibrosis
Mechanism of mesenchymal stem cells in liver regeneration: Insights and future directions
Mesenchymal stem cells (MSCs) are a prevalent source for stem cell therapy and play a crucial role in modulating both innate and adaptive immune responses. Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of tr
Antibody targeting CD38 enzyme shows positive impact in treating systemic sclerosis
Scleroderma is a chronic autoimmune disease of women.Over time, people living with scleroderma develop progressive and irreversible scarring.Scarring, called fibrosis, effects the lungs, heart and kidneys, leading to poor quality of life, disability and a reduced life expectancy.
Targeting and blocking sCD13 protein could lead to systemic sclerosis treatment
Fibrosis, or the scaring of tissue, occurs in many diseases, and is a central component of systemic sclerosis. There are currently no treatments that can reverse fibrosis and the current treatment only has a modest effect on the course of the disease. But research is finding new targets for potential treatments.
Researchers Identify How Kidneys Protect Themselves from Too Much Phosphate
Article title: Endogenous activation of peroxisome proliferator-activated receptor alpha in proximal tubule cells in counteracting phosphate toxicity Authors: Yusuke Katsuma, Isao Matsui, Ayumi Matsumoto, Hiroki Okushima, Atsuhiro Imai, Yusuke Sakaguchi, Takeshi Yamamoto, Masayuki Mizui, Shohei Uchinomiya, Hisakazu Kato, Akio Ojida,…
Current perspectives on mesenchymal stem cells as a potential therapeutic strategy for non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant health challenge, characterized by its widespread prevalence, intricate natural progression and multifaceted pathogenesis. Although NAFLD initially presents as benign fa
UTEP Pharmacy Researchers Develop Potential Treatment for Fibrosis
Researchers at The University of Texas at El Paso are developing a new therapeutic approach that uses nanoparticles for the treatment of skin and lung fibrosis, conditions that can result in severe damage to the body’s tissues.
KRISS Unlocks the Secrets of Wound Healing and Regeneration
The Korea Research Institute of Standards and Science (KRISS) has unveiled a new principle for controlling the microenvironment of biological tissues to promote wound healing and regeneration.
Targeting inflammatory protein could help treat severe asthma
Australian scientists have revealed a promising new treatment for severe asthma, targeting a protein that controls inflammation and scarring of the airways.
Urban Pollution Changes Properties of Lung Cells, Causes Fibrosis
Article title: Complex urban atmosphere alters alveolar stem cells niche properties and drives lung fibrosis Authors: Randa Belgacemi, Bruno Ribeiro Baptista, Grégoire Justeau, Marylène Toigo, Andrew Frauenpreis, Rojda Yilmaz, Audrey Der Vartanian, Mathieu Cazaunau, Edouard Pangui, Antonin Bergé, Aline Gratien,…
Surgery most effective treatment of metabolic liver disease
Metabolic (bariatric) surgery is more effective than medications and lifestyle interventions for the treatment of advanced non-alcoholic fatty liver disease.
Fatty Acid May Be Useful in Preventing Kidney Fibrosis, Treating Fibrotic Diseases
Article title: Epoxyeicosatrienoic acid administration or soluble epoxide hydrolase inhibition attenuates renal fibrogenesis in obstructive nephropathy Authors: Mi Ra Noh, Hee-Seong Jang, Fadi E. Salem, Fernando A. Ferrer, Jinu Kim, Babu J. Padanilam From the authors: “Our findings provide a…
Research reveals how a potentially fatal COVID-19 complication damages lung tissue
Mechanisms involved in the rapid, severe progression of fibrosis in the lung tissues of COVID-19 patients, a potentially fatal complication of the virus that damages and scars the lungs, have been uncovered by researchers led by UTHealth Houston.
Study: First-Degree Relatives of Patients with NAFLD at Risk of Liver Disease
New study identifies that first-degree relatives of patients with nonalcoholic fatty liver disease with advanced fibrosis (scarring of the liver) are at a 15% risk of developing the condition.
How the western diet and gut bacteria can lead to scarring, vessel damage in scleroderma
A substance produced by gut microorganisms can lead to scarring and blood vessel damage in patients with scleroderma, a new study suggests. Researchers say they will examine whether drugs or food products, like virgin olive oil, can block the formation of the compound in the gut to treat fibrosis.
Heart of Aging Female Mice Produce More Collagen than Males, Develops More Scarring
Article title: Sex-specific phenotypes in the aging mouse heart and consequences for chronic fibrosis Authors: Aude Angelini, Jesus Ortiz-Urbina, JoAnn Trial, Anilkumar K. Reddy, Anna Malovannaya, Antrix Jain, Mark L. Entman, George E. Taffet, Katarzyna A. Cieslik From the authors:…
Post-COVID Lung Disease Shares Origins with Other Scarring Lung Disorders
UC San Diego researchers provide first insights into the fundamental cellular pathologies that drive interstitial lung disease in patients post-COVID.
Flu causes cardiac complications by directly infecting the heart
Researchers have shown for the first time in mice that heart problems seen in some of the sickest flu patients are caused by direct influenza infection of cardiac cells.
Drugs showing promise in cancer trials reduce scarring for scleroderma, study shows
Epigenetic drugs that have shown promise in cancer trials significantly reduce scarring in the cells of patients with scleroderma, a new study shows. Results reveal that drugs that inhibit BRD4, known to play a role in cancer, also affect fibrosis in scleroderma. Researchers tested BRD4 inhibitors on the skin fibroblasts of scleroderma patients and in mouse models of skin fibrosis, finding that the treatment stopped scarring in both human-derived cells and in animals.
Microgel coating gives donor cells a boost in reversing pulmonary fibrosis
Researchers have shown that even after lung tissue has been damaged, it may be possible to reverse fibrosis and promote tissue repair through treatment with microgel-coated mesenchymal stromal cells.
Novel Approach Offers Better Understanding of Age-related Muscle Fibrosis
Rockville, Md. (May 13, 2021)—Researchers from the Oklahoma Medical Research Foundation (OMRF) have found a new way to successfully use a stable isotope of water to learn how fibrosis—scarring or hardening—develops in muscle with age. The new approach revealed a…
First time in Thailand – Chula Successfully Uses Stem-cell Transplantation to Treat Systemic Sclerosis Patients with Pulmonary Fibrosis
April 8, 2021 – The Division of Rheumatology, Department of Medicine, Faculty of Medicine (CU Medi), Chulalongkorn University and King Chulalongkorn Memorial Hospital, the Thai Red Cross Society (Chulalongkorn Hospital), in collaboration with the Departments of Hematology, Pulmonary and Critical Care Medicine, and Infectious diseases, held a press conference on “Thailand’s first successful treatment of systemic sclerosis patients with pulmonary fibrosis by stem cell transplantation“.
Bone Marrow SPARC Protein Production Causes Fibrosis in Mouse Hearts
Article title: SPARC production by bone marrow-derived cells contributes to myocardial fibrosis in pressure overload Authors: Hannah J. Riley, Ryan R. Kelly, An O. Van Laer, Lily S. Neff, Shaoni Dasgupta, Catalin F. Baicu, Lindsay T. McDonald, Amanda C. LaRue,…
National Research Effort Discovers Relationship Between Inflammation, Metabolism and Scleroderma Scarring
Study finds NAD+ break down leads to multi organ scarring, providing now a previously undiscovered pathogenic role of the enzyme CD38 in disease scarring.
Three Women Scientists at Johns Hopkins Tapped to Join Exclusive Research Network
Three Johns Hopkins Kimmel Cancer Center scientists are among the first 45 members selected to join the 10x Genomics Visium Clinical Translational Research Network (CTRN), aimed at advancing translational research in some of the world’s leading health problems, including oncology, immuno-oncology, neuroscience, infectious disease, inflammation and fibrosis, and COVID-19.